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Abstract
Background: Relapse of acute lymphoblastic leukemia (ALL) occurring in the breast after allografting is extremely
rare, with only 22 reported cases in the literature thus far. Further, the lack of a systemic analysis provides little
information about this entity. We present a case of isolated extramedullary relapse from acute T lymphoblastic
leukemia (ATLL) after allogeneic hematopoietic stem cell transplantation (HSCT).
Case presentation: A 32-year-old Chinese woman diagnosed with ATLL with myeloid antigen expression received
HSCT from her human leukocyte antigen (HLA)-matched sister and presented with two lesions in her right breast
6 months later. Pathology investigation revealed breast relapse, with complete remission on the basis of bone
marrow findings. Combined modality treatment including chemotherapy and local radiotherapy helped achieve
complete remission with mild side effects.
Conclusion: The findings from this case indicate that the breast is a potentially involved extramedullary site of
relapse for ALL patients after HSCT. In the case of a newly developed breast lump in such patients, clinicians
consider local relapse even if the bone marrow findings indicate remission. Combined modality treatment will
contribute to better local control and improve prognosis.
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Background
Relapse of acute lymphoblastic leukemia (ALL) occurring
in the breast after allografting is extremely rare, with only
22 reported cases in the literature thus far [1–8]. Isolated
extramedullary relapse (IEMR) in the so-called sanctuary
sites after hematopoietic stem cell transplantation (HSCT)
is rarely encountered in clinical practice, especially in the
breast [4]. Given the paucity of data surrounding this
phenomenon, the optimal treatment for relapse of ALL in
the breast has not been identified yet. Systemic chemo-
therapy is generally used. Herein, we describe a rather rare
case of IEMR in the breast after HSCT for acute T
lymphoblastic leukemia (ATLL) in which combined
modality treatment contribute to better local control
and improve prognosis.
Case presentation
In December 2013, a 32-year-old Chinese woman pre-
sented with a 1-month history of intermittent fever. Her
family, psychosocial and past history was unremarkable.
On physical examination, pallor was significant. Neither
lymphadenopathy nor hepatosplenomegaly could be de-
tected. The complete blood cell count examination demon-
strated significantly increased leukocyte (125 × 109 /L) and
decreased hemoglobin (71 g/L) and platelet (17 × 109 /L)
values. The subsequent peripheral blood smears and bone
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Fig. 1 Flow cytometry results of the marrow aspirate at the first visit
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marrow aspirate showed blast cell infiltration of 91 and
89.5 %, respectively. Flow cytometry analysis of the bone
marrow aspirate revealed that the blast cells (P9) accounted
for 91.50 % of the cell population, which predominantly
expressed CD34, CD7, CD33, CD38dim, and HLA-DR;
partly expressed cCD3; seldom expressed cMPO, CD56,
and CD13; and did not express CD117, cCD79a, CD10,
CD19, CD2, CD3, CD99, CD123, CD11b, CD15, CD14,
CD64, CD4, CD11c, CD25, CD36, CXCR4, cTdT, CD5,
CD57, CD1a, and CD8 (Fig. 1). Therefore, the patient was
diagnosed with ATLL with myeloid antigen expression. Fu-
sion gene screening revealed SET-CAN positivity. Induction
chemotherapy using a VDCLP (vincristine, daunorubicin,
cyclophosphamide, L-asparaginase and prednisone) regimen
failed to achieve remission. The treatment was switched
to a CAM (cyclophosphamide, cytarabine and 6-
mercaptopurine) regimen, which induced complete re-
mission (CR). Consolidation chemotherapy including
one cycle of CAM and two cycles of HD-MTX (high
dose methotrexate) was administered during which
intrathecal chemotherapy was provided 12 times.
In May 2014, the patient received allogeneic HSCT
from her human leukocyte antigen (HLA)-matched sister.
The conditioning regimen administered was modified
BU/CY (busulfan/cyclophosphamide). CSA (cyclosporin),
CellCept, and short-term methotrexate (MTX) were
used to prevent graft-versus-host disease (GVHD). We
administered an infusion of 3.2 × 106/kg CD34+ cells
and 11.26 × 108/kg mononuclear cells. Megakaryocyte and
granulocyte engraftment occurred at day +9 and +13, re-
spectively. Bone marrow evaluation at day +14, +28, +42,
+60, +90 indicated CR. Additionally, flow cytometry did
not indicate minimal residual disease. The patient had
100 % donor chimerism. After HSCT, 4 cycles of intra-
thecal chemotherapy were conducted and cerebrospinal
fluid examination results were unremarkable. The post-
transplant course was uneventful, without GVHD.
Six months after HSCT, the patient complained of a
hard lump in the inner upper quadrant of the right breast.
A subsequent breast ultrasound demonstrated two masses
in her right breast. The larger one, located in the inner
upper quadrant, measured approximately 35 mm ×
26 mm × 10 mm with high vascularity and a Breast Im-
aging Reporting and Data System score of 4. The
smaller one, a 9 mm × 4.3 mm hypoechoic nodule, was
located at a 9 o’clock position. The biopsy of the large
lump indicated the presence of a small round cell tumor
(Fig. 2) with an immunohistochemistry profile similar to
that of non-Hodgkin lymphoma: CD20 (-), CD3 (+),
CD56 (+), CK (-), P63 (-), Syn (-), TTF-1 (-), and Ki-67
(+60 %). Bone marrow and cerebrospinal fluid evaluation
revealed no evidence of leukemia. SET-CAN expression
was negative. Therefore, a diagnosis of breast IEMR
was established. After two cycles of chemotherapy with
Fig. 2 Histologic and immunohistochemistry results of the biopsy of the right breast tumor. a The biopsy of the large lump indicated the presence of
a small round cell tumor (HE staining, original magnification, 400×). b The neoplasm exhibited a high Ki-67 proliferation index (60 %, original
magnification, 200×) and stained positive for CD3 (c, original magnification, 200×) and CD56 (d, original magnification, 200×)
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nelarabine (1500 mg/m2, 2310 mg d1, 3, 5, q28d) and one
cycle of chemotherapy with VCP (vincristine, cyclophos-
phamide, and prednisone) -VP (vincristine, and prednis-
one) -VCP -VP, the large lump shrank to 15.6 mm×
5.5 mm. However, the small nodule showed no changes
and caused pain. Positron emission tomography-computed
tomography (PET/CT) demonstrated a moderately FDG
(fluorodeoxyglucose) -avid nodule (standardized uptake
value: 4.6) in the outer upper quadrant of the right breast
and no focal uptake in the other sites (Fig. 3). Subse-
quently, the patient underwent simple intensity-modulated
radiotherapy (sIMRT). The whole right breast received
a dose of 40 Gy/2 Gy/20 f with a concurrent dose of
50 Gy/2.5 Gy/20 f (Fig. 4) to the FDG -avid lump in the
outer upper quadrant. The dose volume histogram
showed excellent dose coverage to the target volume
and minimal dose to the surrounding normal tissue
(Fig. 5). After irradiation of 14 f, the patient did not ex-
perience pain, and the lump in the outer upper quad-
rant disappeared. Furthermore, intensive evaluation of
the bone marrow including cytologic, flow cytometry,
and molecular examination revealed CR. The post-
radiotherapy breast ultrasound also confirmed that the
FDG -avid lump disappeared. Thus, radiotherapy re-
sulted in CR with mild related side effects. Thereafter,
the patient received four cycles of chemotherapy with
decitabine (25 mg d1-5, q28d). The last evaluation of
the bone marrow, conducted 18 months after HSCT,
indicated CR (Fig. 6). The breast ultrasound conducted
on April, 2016, 1 year after radiotherapy, still demon-
strated CR.
Discussion
The most common sites of extramedullary relapse (EMR)
from ALL are the testis and central nervous system [9].
IEMR of the breast in ALL after allogeneic HSCT is ex-
tremely rare. According to the reports by Bekassy et al.
[10], the incidence of breast relapse after HSCT in
leukemia was 0.09 %. IEMR in the breast usually manifests
as bilateral multiple nodules without specific radiologic
Fig. 3 Whole-body positron-emission tomography/computed tomography (PET/CT) findings. a The PET/CT scan demonstrated a hypermetabolic
nodule in right breast and no focal uptake in other sites. The 18 F-FDG-avid nodule was located in the outer upper quadrant of the right breast
with a SUV of 4.6 (b, PET images; c, CT images; d, fused PET/CT images)
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characteristics [7]. In our case, involvement of only the
right breast was an uncommon finding.
The most essential explanation is the protective graft-
versus-leukemia effect on the bone marrow [11]. How-
ever, for extramedullary sites such as the central ner-
vous system and testis, the effect of chemotherapy is
compromised owing to the blood-brain or -testis barrier.
Besides, allogeneic T cells can hardly reach these locations
[12]. Philadelphia positive ALL is considered a high-risk
indicator of relapse and dismal prognosis [7]. Horowitz et
al. pointed out that the presence of GVHD was associated
with a relatively lower risk of relapse in ALL after allo-
geneic HSCT [13]. Our patient did not develop GVHD,
partially illustrating the occurrence of breast IEMR.
Fig. 5 The dose volume histogram of organs at risk and target volume using simple intensity-modulated radiotherapy
Fig. 4 The dose distribution of the simple intensity-modulated radiotherapy
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Additionally, individuals who developed EMR before
HSCT had a much higher risk of relapse in extramedul-
lary site [14, 15]. Another explanation for IEMR is that
blast cells have a high affinity to extramedullary loca-
tions because of specific adhesion molecules or recep-
tors [6].
PET/CT was valuable in detecting EMR after HSCT
even in uncommon sites [16]. In terms of a sensitive,
whole-body imaging modality, PET/CT was helpful in
accurate staging and evaluation of leukemia burden. As
described in our case, PET/CT demonstrated that the
larger lesion disappeared after chemotherapy, while the
smaller one was still FDG -avid. Therefore, further inter-
vention should be initiated to improve local control. The
application of PET/CT is encouraged in cases of EMR
after HSCT for accurate disease staging, delineating
treatment strategies, and response evaluation.
SET-CAN fusion gene was first described in 1992 by
von Lindern M et al. [17, 18] in a case of acute undiffer-
entiated leukemia. SET-CAN positivity generally indi-
cates resistance to chemotherapy, especially to high dose
of glucocorticoids [19]. Van Vlierberghe P et al. pointed
out SET-CAN boosted the progression of ATLL by acti-
vation of HOXA and inhibition of T cell differentiation
[20]. Besides, SET-CAN is a valuable index in the min-
imal residual disease (MRD) monitoring for its high sen-
sitivity. SET-CAN was positive at first visit in our patient
and turned to negative when she suffered breast relapse,
indicating that the bone marrow was CR and the breast
relapse was EMR.
Fig. 6 Flow cytometry results of the bone marrow aspirate obtained at the last follow-up (December 1, 2015) indicated complete remission
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In comparison with its B-lineage ALL counterpart,
IEMR in the breast in ATLL after HSCT is exceedingly
rare. Howrey et al. described the case of a 15-year-old
girl who received an umbilical cord blood transplant for
refractory, relapsed T-cell ALL, and developed breast
IEMR on day +373 after transplantation. Despite local
radiotherapy to the breast mass, bone marrow relapse
occurred over the next several weeks and the patient
eventually died of progressive disease on day 140 after
breast IEMR [21]. Firas et al. described the case of a 27-
year-old woman with common T-ALL with a normal
karyotype who developed IEMR in the left breast and
left axillary lymph nodes on day +345 after allogeneic
HSCT. Local radiotherapy helped achieve CR. However,
on day +519 after HSCT, she experienced myocardial in-
filtration, and subsequent systemic chemotherapy induced
CR. On day +707 after HSCT, relapse in the kidneys and
bone marrow occurred. The patient died shortly thereafter
[2]. In our patient, the HSCT was effective (CR at least
18 months after HSCT). However, long-term surveillance
should be performed to monitor treatment outcomes.
Even though patients with EMR due to leukemia after
allogeneic HSCT usually demonstrate a dismal prognosis,
frequently followed by multiple relapses, they tend to show
long-term survival [10, 15]. The optimal treatment remains
uncertain owing to the rarity of IEMR after HSCT and the
lack of large-scale retrospective studies [2]. Multiple factors
such as the interval between IEMR and HSCT, patient age,
performance status, and prior treatment strategy must be
taken into consideration before a definite therapeutic algo-
rithm is established [10, 15, 22, 23]. In the published cases,
cases of IEMR in the breast demonstrated varying sensitiv-
ity to radiotherapy. In the study by Fadilah et al., a patient
with B-precursor ALL presented with bilateral breast and
ovarian recurrence on day +172 after HSCT. Radiotherapy
of 40 Gy to the breasts resulted in only partial remission.
Subsequent chemotherapy with mitoxantrone, cytosine,
and arabinoside and infusion of donor lymphocytes con-
tributed to CR. Moreover, multidisciplinary intervention
achieved at least 10 months of disease-free survival [5].
However, in the case presented by Conter et al., the breast
IEMR showed strong radiosensitivity at 30 Gy/15 f plus
mild chemotherapy, which brought about rapid disappear-
ance of the tumor [24]. In the case described by Firas et al.,
12 fractions of radiotherapy to the 10 cm tumor in the left
breast and 3 cm left axillary lymph node helped achieve
CR [2]. Radiotherapy might play an essential role in local
control of breast IEMR. One study reported that the lack
of radiotherapy at the first relapse in the right breast in a
patient with ALL following allogeneic HSCT resulted in a
second relapse in the same breast [25]. In our case, the two
lesions in the right breast showed great heterogeneity.
The larger one responded to chemotherapy well while the
smaller one did not. The smaller lesion was resistant to
chemotherapy but radiosensitive. This heterogeneity em-
phasized the importance of combined modality treatment
in the elimination of leukemia cells to the greatest extent.
Conclusions
The breast is a potentially involved site of relapse for
ALL patients after HSCT even without evidence of bone
marrow recurrence. For newly developed breast lumps
in ALL individuals after HSCT, we should consider the
possibility of local relapse despite bone marrow remission.
Close follow-up is critical because early detection of
tumor progression and timely intervention can guarantee a
better prognosis. This case is novel in that it is rare and be-
cause it illustrates the value of PET/CT in disease evalu-
ation and determining the best intervention. In future,
multicentric clinical trials should be conducted to establish
a consensus regarding this unique disease.
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